Morgan Stanley Maintains Equal-Weight on Acadia Pharmaceuticals, Lowers Price Target to $24
Benzinga Newsdesk 14 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Jeffrey Hung maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and lowers the price target from $28 to $24.
Morgan Stanley analyst Jeffrey Hung maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and lowers the price target from $28 to $24.